Biote Corp. (BTMD)

Nasdaq: BTMD · Medicinal Chemicals & Botanical Products · Irving, TX · filing with the SEC since 2020

Full chart Alerts Compare

Grade4.8

◀ Past 4.6● Present 4.2▶ Future 5.6

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$192M-2.5%

Net income$27.0M+756.7%

Earnings per share$0.74+722.2%

Operating cash flow$35.2M-22.2%

Cash$24.1M-38.7%

Debt$95.8M-5.4%

Shareholders’ equity-$58.5M+44.7%

Shares, diluted36.7M+7.0%

Return on equityn/a

The recordfrom its filings

Filings in 202637

Newest filingNov 12 · SCHEDULE 13G/A

Annual reportMar 13, 2026

Quarterly reportNov 9, 2026

Next report due10-K by Mar 16

Insider sales, 12 months$0.00

Insider buys, 12 months$200,000

Patents grantedn/a

Filer categoryAccelerated filer<br>Smaller reporting company<br>Emerging growth company

Trailing twelve months to Sep 2026Revenue $179MNet income -$1.9MCash from operations $14.0Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

2122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Nov 9, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 4, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Sep 18, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Sep 1, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Aug 28, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Aug 12, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Aug 7, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Aug 5, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Jul 27, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Biote Corp. is classed by the SEC under Medicinal Chemicals & Botanical Products (industry code 2833), based in Irving, TX. Pellet Procedures Product Revenue was 71% of fiscal 2025 revenue.

Newest on the record

Large holder update, amended on Nov 12. Before it, quarterly report on Nov 9.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 16, 2027.

About BTMD

Biote Corp. is classed by the SEC under Medicinal Chemicals & Botanical Products (industry code 2833), based in Irving, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $192 million and a profit of $27 million (its filed statements).

IndustryMedicinal Chemicals & Botanical Products

HeadquartersIrving, TX

Business modelProduct business

ExchangeNasdaq

Filing since2020

Fiscal year endsDec 31

SEC number (CIK)1819253

Peers on fileNAGE, FTLF, NAII, MDWD

Who runs it

Financial performance

In fiscal 2025 Biote’s revenue was $192.2 million, down 2.5% from $197.2 million the year before. Net income was $27.05 million, up 756.7%.

Annual report, filed Mar 13, 2026.

Financial statements

The grade

Biote grades 4.8 of 10 against its own industry, the 20 companies in Medicinal Chemicals & Botanical Products. All nine metrics are read as filed.

◀ Past4.6

● Present4.2

▶ Future5.6

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton BTMD · research, not advice